Extension Study Offering Continued Roche Cancer Treatment for Participants From Previous Genentech or Roche Trials

What this Trial Is About

This research is an extension study for participants with cancer who have been previously enrolled in a Genentech andor F. Hoffmann-La Roche sponsored study. It aims to provide continued treatment with Roche investigational medicinal products IMPs either as monotherapy or combined with other agents for those still on study treatment at the time of rollover, particularly when local access to the study treatment is not available. The study is open-label and multicenter, focusing on long-term treatment continuation under medical supervision. Participants will continue receiving Roche IMPs following the same dose, schedule, and administration guidelines as in the parent study. Treatments include monotherapy or combination therapy with drugs such as Ipatasertib, Tiragolumab, Atezolizumab, Bevacizumab, Entrectinib, Inavolisib, and Divarasib. Treatment continues until disease progression, loss of clinical benefit, death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, local treatment availability, or study termination. During the study, participants are monitored for ongoing treatment benefits and adverse events as assessed by standard criteria. Researchers measure the number of participants maintaining access to Roche IMP-based therapy and track the number and severity of selected adverse events over up to approximately 10 years. Safety and treatment effectiveness are evaluated regularly, with participant follow-up continuing as long as treatment is administered or until study completion.

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study